The influence of innate and adaptive immune responses on atherosclerosis

Annual Review of Pathology: Mechanisms of Disease

Volumn 9, Issue , 2014, Pages 73-102

  Witztum, Joseph L ^a   Lichtman, Andrew H ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibodies; B lymphocytes; Cardiovascular disease; Oxidation specific epitopes; T lymphocytes

Indexed keywords

INFLAMMASOME; LIPOPROTEIN; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL; ANTIGEN PRESENTING CELL; ARTERY; ATHEROSCLEROSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; METABOLISM; METHODOLOGY; OXIDATION REDUCTION REACTION; REVIEW; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; ARTERIES; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY; INFLAMMASOMES; LIPOPROTEINS; MACROPHAGES; OXIDATION-REDUCTION; RECEPTORS, SCAVENGER; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84897018581     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-020712-163936     Document Type: Article

References (178)

1. HanssonGK, Robertson AK, Soderberg-Naucler C. 2006. Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis. 1:297-329
2. Tufano A, Di Capua M, Coppola A, Conca P, Cimino E, et al. 2012. The infectious burden in atherothrombosis. Semin. Thromb. Hemost. 38:515-23
3. Wick G, Knoflach M, Xu Q. 2004. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu. Rev. Immunol. 22:361-403
4. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, et al. 2010. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:1357-61
5. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, et al. 2011. Oxidation-specific epitopes are danger-Associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108:235-48
6. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, et al. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200:1359-70
7. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, et al. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation:molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9:736-43
8. ChouMY, FogelstrandL, HartvigsenK, HansenLF, Woelkers D, et al. 2009. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J. Clin. Investig. 119:1335-49
9. Chang MK, Bergmark C, Laurila A, Horkko S, Han KH, et al. 1999. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl. Acad. Sci. USA 96:6353-58
10. Chang MK, Binder CJ, Torzewski M, Witztum JL. 2002. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. USA 99:13043-48
11. Libby P. 2012. Counterregulation rules in atherothrombosis. J. Am. Coll. Cardiol. 59:1438-40
12. Steinberg D, Witztum JL. 2010. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30:2311-16
13. Miller YI, Choi SH, Fang L, Tsimikas S. 2010. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell. Biochem. 51:229-51
14. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, et al. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Investig. 84:1086-95
15. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, Miller YI. 2008. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low-density lipoprotein. J. Biol. Chem. 283:10241-51
16. Zhao L, Funk CD. 2004. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med. 14:191-95
17. Leitinger N. 2003. Cholesteryl ester oxidation products in atherosclerosis. Mol. Asp. Med. 24:239-50
18. Goldstein JL, Ho YK, Basu SK, Brown MS. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 76:333-37
19. Kzhyshkowska J, Neyen C, Gordon S. 2012. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 217:492-502
20. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, et al. 2002. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277:38503-16
21. Freeman M, Ekkel Y, Rohrer L, Penman M, Freedman NJ, et al. 1991. Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low-density lipoprotein. Proc. Natl. Acad. Sci. USA 88:4931-35
22. Witztum JL. 2005. You are right too! J. Clin. Investig. 115:2072-75
23. Greaves DR, Gordon S. 2009. Themacrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J. Lipid Res. 50(Suppl.):282-86
24. Curtiss LK, Tobias PS. 2009. Emerging role of Toll-like receptors in atherosclerosis. J. Lipid Res. 50(Suppl.):340-45
25. Richards MR, Black AS, Bonnet DJ, Barish GD, Woo CW, et al. 2013. The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice. Innate Immun. 19:20-29
26. Higashimori M, Tatro JB, Moore KJ, Mendelsohn ME, Galper JB, Beasley D. 2011. Role of Toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31:50-57
27. Hayashi C, Papadopoulos G, Gudino CV, Weinberg EO, Barth KR, et al. 2012. Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. J. Immunol. 189:3681-88
28. Seimon TA, NadolskiMJ, Liao X, Magallon J, Nguyen M, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12:467-82
29. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, et al. 2010. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11:155-61
30. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, et al. 2010. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 107:737-46
31. Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, et al. 2003. Receptors involved in the oxidized 1- palmitoyl-2-Arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-Anchored protein. J. Biol. Chem. 278:29661-66
32. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, LeitingerN. 2002. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419:77-81
33. Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, et al. 2003. Specific phospholipid oxidation products inhibit ligand activation of Toll-like receptors 4 and 2. Arterioscler. Thromb. Vasc. Biol. 23:1197-203
34. Wiesner P, Choi SH, Almazan F, Benner C, Huang W, et al. 2010. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activatemacrophages via nuclear factor κB and activator protein 1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ. Res. 107:56-65
35. von Schlieffen E, Oskolkova OV, Schabbauer G, Gruber F, Bluml S, et al. 2009. Multi-hit inhibition of circulating and cell-Associated components of theToll-like receptor 4 pathway by oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 29:356-62
36. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, et al. 2011. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478:76-81
37. Lewis MJ. 2009. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120:417-26
38. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. 2002. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Investig.109:745-53
39. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, et al. 2011. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ. Res. 109:830-40
40. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, et al. 2011. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J. Lipid Res. 52:1829-36
41. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin.Investig. 105:1731-40
42. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, et al. 2012. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J. Am. Coll. Cardiol. 60:2218-29
43. Griffin DO, Holodick NE, Rothstein TL. 2011. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70. J. Exp. Med. 208:67-80
44. Ridker PM, Thuren T, Zalewski A, Libby P. 2011. Interleukin-1βinhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162:597-605
45. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, et al. 2003. Lack of interleukin-1βdecreases the severity of atherosclerosis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23:656-60
46. Self-Medlin Y, Byun J, Jacob RF, Mizuno Y, Mason RP. 2009. Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. Biochim. Biophys. Acta 1788:1398-403
47. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, et al. 2010. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5:e11765
48. Menu P, Pellegrin M, Aubert JF, Bouzourene K, Tardivel A, et al. 2011. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2:e137
49. Xu QB, Oberhuber G, GruschwitzM, Wick G. 1990. Immunology of atherosclerosis: cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin. Immunol. Immunopathol. 56:344-59
50. Bobryshev YV, Lord RS. 1995. S-100-positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc. Res. 29:689-96
51. Waltner-Romen M, Falkensammer G, Rabl W, Wick G. 1998. A previously unrecognized site of local accumulation of mononuclear cells. The vascular-Associated lymphoid tissue. J. Histochem. Cytochem. 46:1347-50
52. Bobryshev YV. 2010. Dendritic cells and their role in atherogenesis. Lab. Investig. 90:970-84
53. Paulson KE, Zhu S-N, Chen M, Nurmohamed S, Jongstra-Bilen J, CybulskyMI. 2010. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ. Res. 106:383-90
54. Packard RR, Maganto-Garcia E, Gotsman I, Tabas I, Libby P, Lichtman AH. 2008. CD11c+ dendritic cells maintain antigen processing, presentation capabilities, and CD4+ T cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ. Res. 103:965-73
55. Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, et al. 2012. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J. Clin. Investig. 122:3114-26
56. Grundtman C, Kreutmayer SB, Almanzar G, Wick MC, Wick G. 2011. Heat shock protein 60 and immune inflammatory responses in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31:960-68
57. Gounopoulos P, Merki E, Hansen LF, Choi SH, Tsimikas S. 2007. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 55:821-37
58. Kahlenberg JM, Kaplan MJ. 2013. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu. Rev. Med. 64:249-63
59. Daugherty A. 1997. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J. Clin. Investig. 100:1575-80
60. Zhou X, Nicoletti A, Elhage R, HanssonGK. 2000. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102:2919-22
61. Song L, LeungC, Schindler C. 2001. Lymphocytes are important in early atherosclerosis. J. Clin. Investig. 108:251-59
62. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. 1986. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6:131-38
63. Emeson EE, Robertson AL Jr. 1988. T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis. Am. J. Pathol. 130:369-76
64. Haraoka S, Shimokama T, Watanabe T. 1995. Participation of T lymphocytes in atherogenesis: sequential and quantitative observation of aortic lesions of rats with diet-induced hypercholesterolaemia using en face double immunostaining. Virchows Arch. 426:307-15
65. Roselaar SE, Kakkanathu PX, Daugherty A. 1996. Lymphocyte populations in atherosclerotic lesions of apoE-/- and LDL receptor-/- mice. Decreasing density with disease progression. Arterioscler. Thromb. Vasc. Biol. 16:1013-18
66. Zhou X, Stemme S, Hansson GK. 1996. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein E-deficient mice. Am. J. Pathol. 149:359-66
67. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. 2004. B7-1/B7-2 costimulation regulates plaque antigen-specificTcell responses and atherogenesis in low-density lipoprotein receptor- deficient mice. Circulation 109:2009-15
68. Bergstrom I, Backteman K, Lundberg A, Ernerudh J, Jonasson L. 2012. Persistent accumulation of interferon-γ-producing CD8+CD56+ T cells in blood from patients with coronary artery disease. Atherosclerosis 224:515-20
69. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 92:3893-97
70. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, et al. 2010. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J. Exp. Med. 207:1081-93
71. Ketelhuth DF, Rios FJ, Wang Y, Liu H, JohanssonME, et al. 2011. Identification of a danger-Associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses. Circulation 124:2433-43
72. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, et al. 1999. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophagestimulating cytokines. Atherosclerosis 145:33-43
73. Zhou X, PaulssonG, Stemme S, HanssonGK. 1998. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Investig. 101:1717-25
74. Stemme S. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 92:3893-97
75. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. 2003. Influence of interferon-γon the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 23:454-60
76. Gupta S. 1997. IFN-γpotentiates atherosclerosis in ApoE knock-out mice. J. Clin. Investig. 99:2752-61
77. Whitman SC, Ravisankar P, Elam H, Daugherty A. 2000. Exogenous interferon-γenhances atherosclerosis in apolipoprotein E-/- mice. Am. J. Pathol. 157:1819-24
78. Buono C. 2005. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl Acad. Sci. USA 102:1596-601
79. Lee TS, Yen H-C, Pan C-C, Chau LW. 1999. The role of interleukin 12 in the development of atherosclerosis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:734-42
80. Davenport P, Tipping PG. 2003. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163:1117-25
81. Tzellos T, Kyrgidis A, Zouboulis CC. 2012. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a metaanalysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 27:622-27
82. Gerdes N, SukhovaGK, Libby P, Reynolds RS, Young JL, Schonbeck U. 2002. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. 195:245-57
83. Mallat Z. 2001. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104:1598-603
84. Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE, et al. 2011. Interleukin-18 and coronary heart disease: prospective study and systematic review. Atherosclerosis 217:227-33
85. TiretL, Godefroy T, Lubos E, NicaudV, Tregouet DA, et al. 2005. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112:643-50
86. Hernesniemi JA, Heikkila? A, Raitakari OT, Kahonen M, Juonala M, et al. 2010. Interleukin-18 gene polymorphism and markers of subclinical atherosclerosis. TheCardiovascular Risk in Young Finns Study. Ann. Med. 42:223-30
87. Whitman SC, Ravisankar P, Daugherty A. 2002. Interleukin-18 enhances atherosclerosis in apolipoprotein E-/- mice through release of interferon-γ. Circ. Res. 90:E34-38
88. Elhage R, Jawien J, Rudling M, Ljunggren H-G, Takeda K, et al. 2003. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59:234-40
89. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. 2011. Recent advances on the role of cytokines in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31:969-79
90. King VL, Szilvassy SJ, Daugherty A. 2002. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 22:456-61
91. Weaver CT, Elson CO, Fouser LA, Kolls JK. 2013. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu. Rev. Pathol. Mech. Dis. 8:477-512
92. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, et al. 2009. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206:2067-77
93. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, et al. 2010. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J. Pathol. 220:499-508
94. Eid RE. 2009. Interleukin-17 and interferon-γare produced concomitantly by human coronary artery- infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119:1424-32
95. Erbel C. 2009. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J. Immunol. 183:8167-75
96. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, et al. 2010. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121:1746-55
97. ButcherMJ, Gjurich BN, PhillipsT, GalkinaEV. 2012.The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ. Res. 110:675-87
98. Danzaki K, Matsui Y, Ikesue M, Ohta D, Ito K, et al. 2012. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32:273-80
99. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, et al. 2010. B cell depletion reduces the development of atherosclerosis in mice. J. Exp. Med. 207:1579-87
100. WuHJ, Ivanov II, Darce J, Hattori K, Shima T, et al. 2010. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32:815-27
101. Waisman A. 2012. To be 17 again-Anti-interleukin-17 treatment for psoriasis. N. Engl. J. Med. 366:1251-52
102. van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. 1989. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab. Investig. 61:166-70
103. Olofsson PS, Soderstrom LA, Wagsater D, Sheikine Y, Ocaya P, et al. 2008. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117:1292-301
104. Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. 2007. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J. Clin. Investig. 117:2974-82
105. Bu DX, TarrioM, Maganto-Garcia E, StavrakisG, TajimaG, et al. 2011. Impairment of the programmed cell death 1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 31:1100-7
106. Elhage R, Gourdy P, Brouchet L, Jawien J, Fouque MJ, et al. 2004. Deleting TCR αβ+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am. J. Pathol. 165:2013-18
107. Kolbus D, Ljungcrantz I, Soderberg I, Alm R, BjorkbackaH, et al. 2012. TAP1-deficiency does not alter atherosclerosis development in apoE-/- mice. PLoS ONE 7:e33932
108. Kyaw T, Winship A, Tay C, Kanellakis P, HosseiniH, et al. 2013. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-/- mice. Circulation 127:1028-39
109. Brennan PJ, Brigl M, Brenner MB. 2013. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13:101-17
110. Getz GS, Vanderlaan PA, Reardon CA. 2011. Natural killer T cells in lipoprotein metabolism and atherosclerosis. Thromb. Haemost 106:814-19
111. Bobryshev YV, Lord RS. 2005. Co-Accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J. Histochem. Cytochem. 53:781-85
112. Melian A, Geng YJ, Sukhova GK, Libby P, Porcelli SA. 1999. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am. J. Pathol. 155:775-86
113. Dumitriu IE, Araguas ET, Baboonian C, Kaski JC. 2009. CD4+CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc. Res. 81:11-19
114. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, et al. 2000. Monoclonal T cell proliferation and plaque instability in acute coronary syndromes. Circulation 101:2883-88
115. Zal B, Kaski JC, Arno G, Akiyu JP, Xu Q, et al. 2004. Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation 109:1230-35
116. Tsimikas S, PalinskiW, Witztum JL. 2001. Circulating autoantibodies to oxidizedLDLcorrelatewith arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21:95-100
117. Palinski W, Miller E, Witztum JL. 1995. Immunization of low density lipoprotein (LDL) receptor- deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA 92:821-25
118. Hansson GK, Nilsson J. 2009. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin. Immunopathol. 31:95-101
119. Nilsson J, Bjorkbacka H, Fredrikson GN. 2012. Apolipoprotein B100 autoimmunity and atherosclerosis-disease mechanisms and therapeutic potential. Curr. Opin. Lipidol. 23:422-28
120. Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, et al. 2011. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J. Am. Coll. Cardiol. 58:1715-27
121. MajorAS, Fazio S, Linton MF. 2002.Blymphocyte deficiency increases atherosclerosis inLDLreceptor- null mice. Arterioscler. Thromb. Vasc. Biol. 22:1892-98
122. Doran AC, Lipinski MJ, Oldham SN, Garmey JC, Campbell KA, et al. 2012. B cell aortic homing and atheroprotection depend on Id3. Circ. Res. 110:e1-12
123. Kyaw T, TayC, Khan A, Dumouchel V, Cao A, et al. 2010. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J. Immunol. 185:4410-19
124. Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, et al. 2012. Depletion of B2 but not B1α B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS ONE 7:e29371
125. Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, et al. 2012. BAFF receptor deficiency reduces the development of atherosclerosis in mice-brief report. Arterioscler. Thromb. Vasc. Biol. 32:1573-76
126. Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, et al. 2010. Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc. Res. 85:224-31
127. Hernandez-Vargas P, Ortiz-Munoz G, Lopez-Franco O, Suzuki Y, Gallego-Delgado J, et al. 2006. Fcγ receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ. Res. 99:1188-96
128. Zhao M, Wigren M, Dunar P, Kolbus D, Olofsson KE, et al. 2010. FcγRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J. Immunol. 184:2253-60
129. Mendez-Fernandez YV, Stevenson BG, Diehl CJ, Braun NA, Wade NS, et al. 2011. The inhibitory FcγRIIb modulates the inflammatory response and influences atherosclerosis in male apoE-/- mice. Atherosclerosis 214:73-80
130. Wang J, Cheng X, Xiang MX, Alanne-Kinnunen M, Wang JA, et al. 2011. IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in apoE-/- mice. J. Clin. Investig. 121:3564-77
131. Speidl WS, Kastl SP, Huber K, Wojta J. 2011. Complement in atherosclerosis: friend or foe? J. Thromb. Haemost. 9:428-40
132. Lichtman AH. 2012. T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases. Front. Physiol. 3:18
133. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. 2013. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J. Clin. Investig. 123:27-36
134. Ma K, Lv S, Liu B, Liu Z, Luo Y, et al. 2013. CTLA4-IgG ameliorates homocysteine-Accelerated atherosclerosis by inhibiting T cell overactivation in apoE-/- mice. Cardiovasc. Res. 97:349-59
135. Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, et al. 2013. T cell co-stimulation by CD28- CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int. J. Cardiol. 168:1965-74
136. Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, et al. 2005. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat. Genet. 37:365-72
137. vanWanrooijEJ, vanPuijveldeGH, deVos P, Yagita H, vanBerkelTJ, Kuiper J. 2007. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor- deficient mice. Arterioscler. Thromb. Vasc. Biol. 27:204-10
138. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. 2000. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 97:7458-63
139. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. 1998. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394:200-3
140. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, et al. 1999. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5:1313-16
141. LievensD, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. 2009. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb. Haemost. 102:206-14
142. Lee J, Zhuang Y, Wei X, Shang F, Wang J, et al. 2009. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J. Mol. Cell Cardiol. 46:169-76
143. Josefowicz SZ, Lu LF, Rudensky AY. 2012. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30:531-64
144. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC. 2007. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE 2:e779
145. Patel S, Chung SH, White G, Bao S, Celermajer DS. 2010. The "atheroprotective" mediators apolipoproteinA-I and Foxp3 are over-Abundant in unstable carotid plaques. Int. J. Cardiol. 145:183-87
146. Zhang WC, Wang J, Shu YW, Tang TT, Zhu ZF, et al. 2012. Impaired thymic export and increased apoptosis account for regulatoryTcell defects in patients with non-ST segment elevation acute coronary syndrome. J. Biol. Chem. 287:34157-66
147. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, et al. 2010. Circulating CD4+CD25hiCD127lo regulatory T cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30:1832-41
148. Potekhina AV, Provatorov SI, Sokolov VO, Pylaeva EA, Masenko VP, et al. 2011. CD4+CD25highCD127low regulatory T cells in patients with stable angina and their dynamics after intracoronary sirolimus-eluting stent implantation. Hum. Immunol. 72:553-57
149. Zhang D, Wang S, Guan Y, Wang L, Xie W, et al. 2011. Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention. J. Cardiovasc. Pharmacol. 57:536-41
150. Bu DX, Griffin G, Lichtman AH. 2011. Mechanisms for the anti-inflammatory effects of statins. Curr. Opin. Lipidol. 22:165-70
151. Entin-Meer M, Afek A, George J. 2009. Regulatory T cells, FoxP3 and atherosclerosis. Adv. Exp. Med. Biol. 665:106-14
152. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, et al. 2006. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12:178-80
153. Gotsman I, Gupta R, Lichtman AH. 2006. Impaired regulatoryTcell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114:2047-55
154. Ng HP, Burris RL, Nagarajan S. 2011. Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J. Immunol. 187:6082-93
155. Weber C, Meiler S, Doring Y, Koch M, Drechsler M, et al. 2011. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis inmice. J. Clin. Investig. 121:2898-910
156. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, et al. 2007. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27:2691-98
157. Dietrich T, Hucko T, Schneemann C, Neumann M, Menrad A, et al. 2012. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells. Atherosclerosis 220:329-36
158. Foks AC, Frodermann V, ter Borg M, Habets KLL, Bot I, et al. 2011. Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis 218:53-60
159. Dinh TN, Kyaw TS, Kanellakis P, To K, Tipping P, et al. 2012. Cytokine therapy with interleukin- 2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis: clinical perspective. Circulation 126:1256-66
160. Sasaki N, Yamashita T, Takeda M, Shinohara M, Nakajima K, et al. 2009. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 120:1996-2005
161. Maganto-Garcia E, Tarrio ML, Grabie N, Bu D, Lichtman AH. 2011. Dynamic changes in aortic regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation 24:185-95
162. Robertson AK. 2003. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Investig. 112:1342-50
163. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, et al. 2004. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 24:1474-78
164. Subramanian M, Thorp E, Hansson GK, Tabas I. 2013. Treg-mediated suppression of atherosclerosis requires MyD88 signaling in DCs. J. Clin. Investig. 123:179-88
165. Klingenberg R, Ketelhuth DFJ, Strodthoff D, Gregori S, Hansson GK. 2012. Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in apoE-/- mice. Immunobiology 217:540-47
166. Herbin O, Ait-Oufella H, Yu W, Fredrikson GN, Aubier B, et al. 2012. Regulatory T cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32:605-12
167. Wigren M, Kolbus D, Dunar P, Ljungcrantz I, Soderberg I, et al. 2011. Evidence for a role of regulatory Tcells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J. Int. Med. 269:546-56
168. Dunar P, To F, Beckmann K, Bjorkbacka H, Fredrikson GN, et al. 2011. Immunization of apoE-/- mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis. Cardiovasc. Res. 91:528-36
169. Klingenberg R. 2010. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30:946-52
170. van Puijvelde GH. 2006. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114:1968-76
171. Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. 2011. Immunotherapy with tolerogenic apolipoprotein B100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 123:1083-91
172. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, et al. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359:2195-207
173. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. 2009. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175-82
174. Ridker P. 2012. Moving beyond JUPITER: Will inhibiting inflammation reduce vascular event rates? Curr. Atheroscler. Rep. 15:1-6
175. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, et al. 2002. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106:1390-96
176. Ridker PM. 2009. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost. 7(Suppl. 1):332-39
177. Micha R, Imamura F, Wyler von Ballmoos M, SolomonDH, Hernan MA, et al. 2011. Systematic review and meta-Analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol. 108:1362-70
178. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, et al. 2008. Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 58:667-77